Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.

Thermo Fisher Scientific announced several product and collaboration updates earlier this month, including the cGMP-ready Gibco CHO-K1 Catalog Panel for bioprocessing, a reseller agreement to distribute Evosep's Eno separation platform in proteomics workflows, and expanded involvement in molecular residual disease programs with Biodesix and Memorial Sloan Kettering. Together, the moves deepen Thermo Fisher's role across biologics manufacturing, advanced proteomics, and ctDNA-based cancer monitoring. The Gibco CHO-K1 Catalog Panel sits within Thermo Fisher's biopharma solutions stack alongside offerings such as CTS OpTmizer and CHOvantage cell line tools, and is positioned to support customers from development through manufacturing. Thermo Fisher's narrative projects $54.8 billion revenue and $10.0 billion earnings by 2029, with a $645.15 fair value implying 5% downside to its current price, while some of the lowest ranked analysts assume only about US$54.2 billion of revenue and US$8.7 billion of earnings by 2029. The company said persistent China and tariff risks remain a consideration for investors.

Gilead Sciences and Thermo Fisher Scientific each raised their full-year outlooks after reporting stronger quarterly results, though their growth profiles differ sharply. Gilead's second-quarter product sales excluding Veklury rose 10% to $7.6 billion, with HIV sales up 12% to $5.7 billion, Biktarvy up 7% to $3.8 billion, Descovy up 48% to $967 million, and Yeztugo generating $232 million versus $15 million a year earlier, prompting management to guide 2026 product sales of $30.1 billion to $30.4 billion and product sales excluding Veklury of $29.8 billion to $30.1 billion. Thermo Fisher reported fiscal second-quarter revenue up 10% to $11.99 billion, including 5% organic growth, with adjusted EPS up 13% to $6.03 and adjusted operating margin expanding to 22.8% from 21.9%, and raised its full-year adjusted EPS outlook to $24.93 to $25.33 from $24.64 to $25.12. Gilead's growth carries concentration risk, as HIV accounted for $5.69 billion of its $7.63 billion in quarterly product sales, while $11.2 billion in acquired in-process R&D tied to the Arcellx, Tubulis and Ouro Medicines deals drove GAAP and non-GAAP losses per share of $8.45 and $6.75. Thermo Fisher's broader base depends on a durable recovery in customer spending, with organic growth accelerating from 1% in the first quarter to 5% and China returning to growth even as academic and government demand there remained subdued.

Evosep announced a reseller agreement under which Thermo Fisher Scientific will offer the Evosep Eno separation platform as part of its portfolio of mass spectrometry solutions. The deal combines Thermo Fisher Scientific's global commercial reach and mass spectrometry instruments with Evosep's separation technology, letting laboratories purchase Evosep Eno directly through Thermo Fisher Scientific. Evosep said the platform was developed to meet growing demand for standardized proteomics in research, drug discovery, and clinical applications, delivering robustness, ease of use, and high throughput. Morten Bern, CEO of Evosep, said the agreement makes Thermo Fisher an ideal partner to expand access to Evosep Eno and to help researchers implement standardized proteomics workflows that deliver robust and reproducible results at scale. Evosep will be at Booth #220 during the HUPO 2026 conference, where members of the media are invited to a discussion on the future of proteomics workflows.

The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a Mayo Clinic-controlled company that will build one of the world's leading biomedical datasets to identify signs of disease before symptoms appear. Mayo Clinic will serve as majority owner and Thermo Fisher joins as minority owner of the venture, which will generate molecular data from one million biospecimens linked with longitudinal clinical information collected over several years. The effort integrates proteomic, genomic and clinical data, with Thermo Fisher contributing its Olink Explore HT proteomics platform and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents. Precure, LLC complements Precure Research, Mayo Clinic's investigator-led scientific effort, by providing the scale, infrastructure and collaborations needed to generate population-scale molecular data and translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic said any financial returns from its involvement would be reinvested in its nonprofit mission of patient care, research and education.

Thermo Fisher Scientific Inc. has launched the Thermo Scientific EMPAD G2 detector, a high-speed four-dimensional scanning transmission electron microscopy (4D STEM) system designed to help researchers analyze materials in unprecedented detail, a development expected to bolster the company's Analytical Instruments segment. Following the announcement, TMO shares dipped slightly by 0.8% last Thursday, but the company has steadily ramped up R&D investments, fueling new product launches and enhancing its portfolio. Thermo Fisher has a market capitalization of $233.20 billion, an earnings yield of 4% well ahead of the industry's -1.3% yield, and has surpassed earnings estimates in each of the trailing four quarters with an average surprise of 4.4%. The EMPAD G2 runs at 10,000 frames per second with high dynamic range and single-electron sensitivity, and is integrated with the Thermo Scientific Velox software for simultaneous 4D STEM and energy-dispersive x-ray spectroscopy analysis. Per a QYResearch report, the global 4D STEM market was valued at an estimated $68 million in 2024 and is projected to reach $110 million by 2031, reflecting a CAGR of 6.6% from 2025 to 2031. In the past year, TMO shares have risen 25.3% against the industry's 4.1% decline.

Abbott Laboratories and Thermo Fisher Scientific both reported encouraging quarterly results, with Abbott's diagnostics segment sales rising 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion. Abbott reaffirmed its full-year comparable sales growth guidance of 6.5% to 7.5%, while Thermo Fisher's organic revenue increased 5%, signaling a potential recovery in life sciences spending. Thermo Fisher's management highlighted improving customer activity across pharmaceutical and biotechnology markets, and its Analytical Instruments business returned to growth after nearly two years of weak demand. Abbott's diversified portfolio across diagnostics, medical devices, and nutrition provides resilience, while Thermo Fisher's outlook depends more heavily on continued recovery in pharmaceutical and biotechnology spending.

Simply Wall St has raised its Fair Value Estimate for Thermo Fisher Scientific from US$590.77 to US$631.42, a 6.9% increase driven by Q2 strength and analyst revisions. The updated model reflects revenue growth of 5.76%, net profit margin of 18.01%, a future P/E of 28.62x, and a discount rate of 8.33%. Morgan Stanley, Barclays, and BofA raised price targets into the US$650 range, while Jefferies lifted its target to US$630 citing a broad-based Q2 beat and higher 2026 core growth outlook. HSBC cut its target to US$540 with a Hold rating, questioning the company's 7% organic growth ambition, and Piper Sandler raised its target to US$600 but remains Neutral pending clearer growth drivers.

LivaNova reported record second-quarter revenue and earnings per share and raised its full-year 2026 outlook. Revenue rose 9.8% on a constant currency basis to $391 million, with Cardiopulmonary revenue up 10% to $222 million and Epilepsy revenue up 10%. The company now expects full-year revenue growth of 8% to 9%, up from 7% to 8%, and adjusted diluted earnings per share of $4.30 to $4.40, up from prior guidance. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for a critical oxygenator component and said it expects to submit a PMA supplement for its next-generation OSA system between the second half of 2026 and the first half of 2027.

Thermo Fisher Scientific received FDA 510(k) clearance for its EXENT Solution, an automated mass spectrometry platform for multiple myeloma. The clearance was highlighted at the ADLM conference in Anaheim in late July 2026, alongside the EliA CTD 13 Screen for autoimmune connective tissue diseases. The EXENT clearance strengthens Thermo Fisher's specialty diagnostics presence in oncology and supports its strategy of linking high-complexity diagnostics with integrated software and standardized clinical decision support. The company's investment narrative projects $54.1 billion in revenue and $9.5 billion in earnings by 2029, requiring 6.2% annual revenue growth from a current earnings base of $6.8 billion.

Thermo Fisher Scientific and Danaher reported diverging second-quarter results, with Thermo Fisher raising its full-year guidance while Danaher lowered the upper end of its core revenue growth outlook. Thermo Fisher's revenue grew 10% to $11.99 billion, with adjusted EPS up 13% to $6.03, driven by broad-based demand improvement across pharmaceutical and biotech markets. Danaher's core growth improved sequentially but was marked by uneven recovery, including a $100 million revenue shift into next year due to customer project timing. Hedge fund ownership of Thermo Fisher rose to 115 funds in the first quarter of 2026 from 113 in the prior quarter, while Danaher's fell from 125 to 110 funds over the same period.

The global bioinformatics market is projected to grow from $20.9 billion in 2024 to $43.5 billion by 2030, a compound annual growth rate of 13.1%, according to a new report by BCC Research. North America holds a 47.7% share, driven by institutional investment in genomic research and a mature biopharma ecosystem. Key drivers include AI and cloud computing integration, rising demand for personalized medicine and oncology applications, and emerging technologies such as long-read sequencing and single-cell multiomics. Major companies in the space include Illumina, Thermo Fisher Scientific, Agilent Technologies, and Dassault Systèmes.

Thermo Fisher Scientific reported total revenue of $11.99 billion for the quarter ended June 2026, up 10.5% from the prior-year period, with international segments showing mixed results against analyst estimates. Revenue from Other regions reached $430 million, or 3.6% of the total, exceeding the consensus estimate of $368.27 million by 16.76%. Asia-Pacific contributed $2.1 billion, or 17.5% of total revenue, falling 1.87% short of the $2.14 billion forecast. Europe generated $3.31 billion, or 27.6% of total revenue, surpassing the $3 billion consensus by 10.46%. For the current quarter, Wall Street expects total revenue of $11.91 billion, with Other regions, Asia-Pacific, and Europe projected to contribute 3.2%, 18.4%, and 25.7% respectively.

Thermo Fisher Scientific reported strong fiscal second-quarter 2026 results, with revenue growing 10% to $11.99 billion and adjusted earnings per share rising 13% to $6.03. The company expanded its portfolio with new analytical instruments including the Orbitrap Tribrid Apex Mass Spectrometer, and its Life Sciences Solutions segment saw reported revenue climb 13% year over year. The Analytical Instruments segment returned to growth after two years of muted demand, while adjusted operating margin expanded to 22.8%. Several analysts raised their price targets, with RBC Capital lifting its target to $580 from $490, and management raised full-year revenue guidance to a range of $47.4 billion to $48.1 billion. Hedge fund ownership increased modestly from 113 funds in the fourth quarter of 2025 to 115 funds in the first quarter of 2026, though the stock trades at roughly 22 times forward earnings, a 15.45% premium to the sector.

DCLA managing partner Sarat Sethi expressed concern about massive AI capital expenditure plans at tech companies outside of Alphabet, while calling Alphabet a core portfolio holding because its diversified businesses give it many levers to toggle. He pointed to YouTube, Cloud, and Gemini as reasons Alphabet can adjust spending if returns on investment do not materialize. Sethi noted a divergence between hardware and software spending, with customers holding back on hardware while continuing to invest in software and security, citing IBM and SAP commentary. He said Microsoft faces particular scrutiny and must show return on investment faster than others, as the stock is already down double digits this year. Beyond tech, Sethi highlighted a rotation into high-quality, cash-flow-generating healthcare companies such as Stryker, Thermo Fisher, and Johnson & Johnson, noting the healthcare sector has shrunk to its smallest S&P 500 weighting ever.

President Donald Trump announced phased tariffs on generic drug imports, starting with zero tariffs for two years from August 1, then rising to 100% in August 2028 and 200% a year later, to push production onshore. Novo Nordisk sued Eli Lilly over ads comparing their GLP-1 weight-loss drugs, alleging misleading efficacy claims. Molina Healthcare shares fell about 11% despite beating second-quarter estimates, as its medical care ratio reached 92.2%. Repligen agreed to acquire BioLife Solutions for about $1.5 billion in a stock-and-cash deal. Roche shares jumped roughly 5% after the company reiterated its 2026 outlook, while Thermo Fisher Scientific raised its full-year guidance following better-than-expected second-quarter results.

Thermo Fisher reported second-quarter 2026 revenue of $11.99 billion, beating analyst estimates of $11.72 billion and representing 10.5% year-on-year growth. Adjusted earnings per share came in at $6.03, surpassing the consensus estimate of $5.71. CEO Marc Casper highlighted broad-based momentum across pharmaceutical, biotech, industrial, and diagnostics markets, with biotech recovery translating into revenue gains. New product launches, including next-generation Orbitrap mass spectrometers and AI-driven software, contributed to market share gains. The company also benefited from the integration of recent acquisitions Clario and filtration and separation businesses, while planning the divestiture of its microbiology business to sharpen focus on higher-growth areas.

Several major companies reported quarterly results. Thermo Fisher Scientific shares jumped 8.7% after second-quarter 2026 revenues of $11.99 billion beat the Zacks Consensus Estimate of $11.68 billion. Tesla shares plunged 14.5% after earnings of 33 cents per share missed the Zacks Consensus Estimate of 50 cents. Union Pacific shares gained 4% after revenues of $6.84 billion beat the estimate of $6.65 billion. CSX shares rose 5.8% after earnings of 54 cents per share beat the estimate of 50 cents.

Thermo Fisher Scientific has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific's pharmaceutical services portfolio, focused on complex drug development work. The Kapiglucagon mandate is part of a broader industry shift in which drug developers frequently work with external partners for specialized development and production capabilities. Thermo Fisher Scientific reported second quarter 2026 sales of US$11.99 billion and net income of US$1.74 billion, and continued to return capital via share repurchases.

US stock futures are pointing lower this morning, with E mini S&P 500 contracts down about 0.4%, as investors react to higher borrowing costs and a jump in market volatility. The US 10 year Treasury yield is sitting near a two month high around 4.65%, raising costs for mortgages, car loans, and business financing, while crude oil strength and geopolitical tensions feed worries that the cost of living could stay elevated for longer. Among top movers, Lockheed Martin jumped 10.54% after Q2 results showed higher sales and net income, United Rentals gained 10.11% following a Q2 beat and higher guidance, and Thermo Fisher Scientific climbed 8.71% on strong Q2 earnings and raised guidance. On the losing side, Tesla fell 14.52% after Q2 earnings and multiple analyst price target cuts, T-Mobile US declined 10.75% despite Q2 revenue growth and a higher price target from Goldman Sachs, and Rollins dropped 9.27% following a downgrade to Underperform. On the radar, earnings from American Express, SLB, Verizon, NextEra Energy, and HCA Healthcare share the spotlight with key US manufacturing data.

Thermo Fisher Scientific shares rose 8.71 percent on Thursday to close at $572.32 after the company reported strong second-quarter earnings and received price target upgrades from three investment firms. Net income grew 7 percent to $1.736 billion from $1.617 billion a year earlier, while revenue increased 10 percent to $11.99 billion from $10.85 billion, driven by its PPI Business System and growth strategy. Jefferies raised its price target to $630 from $585 with a buy rating, Leerink Partners lifted its target to $620 from $600 with an outperform rating, and Evercore ISI upgraded its target to $615 from $570 while reiterating an outperform rating. The company also declared a quarterly dividend of $0.47 per share, payable on October 15 to shareholders of record as of September 15, 2026.

Thermo Fisher Scientific reported second-quarter 2026 adjusted earnings of $6.03 per share, up 13% year over year and beating the Zacks Consensus Estimate by 5.6%. Revenues rose 10% to $11.99 billion, surpassing the consensus mark by 2.67%, supported by 5% organic revenue growth and strengthening customer activity across end markets. The company's four business segments all posted gains, with Life Sciences Solutions revenues increasing 12.6% to $2.82 billion, Laboratory Products and Biopharma Services climbing 11.6% to $6.69 billion, Analytical Instruments advancing 6.9% to $1.85 billion, and Specialty Diagnostics growing 6.3% to $1.21 billion. Adjusted operating income increased 15% to $2.74 billion, and the adjusted operating margin widened 90 basis points to 22.8%. Thermo Fisher also repurchased $1 billion of stock during the quarter and announced the divestiture of its microbiology business. Following the earnings announcement, TMO stock rose 4.4% in pre-market trading.

Seeing Machines has won a new driver monitoring contract with a European carmaker worth around $5 million in lifetime revenue, as new EU safety rules make the technology mandatory on new vehicles. Production starts in 2028, with the system built into a rear-view mirror for easy deployment across multiple platforms. Frontier IP portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology and appointed a China-based distributor with over 100 customers globally. ImmuPharma has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon, completing the main manufacturing partnerships alongside Swiss group Bachem, which is handling the active ingredient. MP Evans grew crude palm oil production 11% to 192,300 tonnes in the first half, supported by higher harvests across its Indonesian estates, with pricing holding firm at around $873 per tonne. Ariana Resources says its Tavşan gold mine in Türkiye has completed its ramp-up and is now processing ore at the required rate of at least 4,000 tonnes a day, with gold recovery tracking at around 70%. 88 Energy has moved its Augusta-1 Alaska well closer to a first-quarter 2027 spud after securing a rig and camp, and prospective resources at South Prudhoe have been upgraded by 35%.

The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.

The global mass spectrometry market is projected to grow from USD 6.68 billion in 2025 to USD 14.09 billion by 2035, at a compound annual growth rate of 7.74 percent, according to a new report by SNS Insider. The instruments segment held a dominant 71.34 percent market share in 2025, while the software and services category is the fastest-growing at a CAGR of 8.92 percent. North America leads the market, with the U.S. market alone valued at USD 2.38 billion in 2025 and expected to reach USD 4.97 billion by 2035, while Asia Pacific is the fastest-growing region at a CAGR of 9.12 percent. Key drivers include rising adoption in pharmaceutical manufacturing, omics research, and clinical diagnostics, with recent product launches such as Thermo Fisher Scientific's Orbitrap Astral mass spectrometer and Agilent Technologies' next-generation triple quadrupole LC-MS/MS system.

The global life science tools market is projected to grow from USD 175.96 billion in 2025 to USD 503.69 billion by 2035, at a compound annual growth rate of 11.09%, according to a new report by SNS Insider. North America led the market in 2025, with the U.S. segment valued at USD 68.50 billion and forecast to reach USD 189.48 billion by 2035, while the Asia-Pacific region is expected to record the fastest growth at a CAGR of more than 12%. Next-generation sequencing held the largest technology share at over 30% in 2025 and is also the fastest-growing technology segment, driven by applications in single-cell sequencing, liquid biopsy, and rare diseases. Instruments accounted for more than 52% of the market by type, and biopharmaceutical companies represented the largest end-user segment with an estimated 44% share. Key players include Agilent Technologies, Illumina, Thermo Fisher Scientific, and Danaher, with recent developments such as Agilent's expansion of its genomics portfolio in 2025 and Illumina's enhanced sequencing platforms in 2024.

The global laboratory plasticware market is projected to grow from US$ 2.25 billion in 2024 to US$ 2.99 billion by 2034, at a compound annual growth rate of 4.72%, according to a new report from Zion Market Research. The market is driven by expanding life sciences research, drug discovery, and the shift from glass to durable, low-cost plastics. Low-density polyethylene (LDPE) leads the material segment with a 29% share, while diagnostic centers dominate end-users with a 37% share. Asia Pacific holds the largest regional share, fueled by manufacturing capabilities and healthcare investments in China and India. Key players include Thermo Fisher Scientific, Eppendorf, Corning, and Sartorius.

The global laboratory centrifuges market is projected to grow from USD 1.58 billion in 2025 to USD 1.86 billion by 2030, at a compound annual growth rate of 2.8%. Equipment held the largest product segment share in 2025, driven by technology upgrades and replacement cycles. Benchtop centrifuges led the platform segment due to their affordability and compact footprint, while hospitals remained the largest end-user segment because of high diagnostic testing volumes. Asia Pacific is expected to register the highest regional growth rate, fueled by healthcare infrastructure investments in China and India. Key players include Thermo Fisher Scientific, Danaher, and Eppendorf.

The global market for dye-free and label-free packaging for polymerase chain reaction optimization is projected to grow from $0.94 billion in 2025 to $1.06 billion in 2026, and further to $1.74 billion by 2030, at a compound annual growth rate of 13.2%. Growth is driven by rising demand for precision genomic testing, sustainable PCR packaging materials, and automated workflow systems, alongside expansion in personalized medicine and molecular diagnostics. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region. Major companies include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., and Bio-Rad Laboratories Inc.

The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.

Thermo Fisher Scientific announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share. The dividend is payable on October 15, 2026, to shareholders of record as of September 15, 2026.

Thermo Fisher Scientific announced that its Applied Biosystems RapidINTEL Plus Cartridge has received approval from the FBI National DNA Index System for use with qualifying forensic crime scene samples. This makes the RapidHIT ID System the first Rapid DNA workflow eligible to generate DNA profiles that can be searched against the national CODIS database network when FBI requirements are met. The approval enables law enforcement to potentially match evidentiary samples to suspects in hours rather than days or weeks, accelerating investigations while maintaining FBI quality standards, laboratory oversight, and accredited laboratory review. Connecticut investigators using Rapid DNA technology generated an investigative lead in approximately 90 minutes for evidence that traditionally required about 90 days to process. The workflow is intended for accredited forensic laboratories and does not replace traditional forensic DNA testing.

The global exosome diagnostics market is projected to reach USD 815.0 million by 2031, growing at a compound annual growth rate of 11.8% from USD 466.2 million in 2026. Growth is driven by rising demand for minimally invasive diagnostics, advancements in biomarker discovery, and increasing adoption of liquid biopsy technologies, particularly in oncology. North America leads the market due to advanced healthcare infrastructure, while Asia-Pacific is expected to see rapid expansion fueled by investments in countries like China and India. Key players include Danaher Corporation, Thermo Fisher Scientific, and Exosome Diagnostics Inc., with competition centered on product innovation and strategic partnerships. Challenges include standardization of exosome isolation and regulatory uncertainty.

Arcturus Therapeutics has entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis. Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research, and related services, leveraging its Accelerator Drug Development solutions. If Phase 2 yields positive results, Arcturus expects to conduct the Phase 3 program through Thermo Fisher's PPD clinical research business. Subject to regulatory approval, Thermo Fisher will receive exclusive commercial manufacturing rights under a separate commercial agreement. The collaboration aims to accelerate development of ARCT-032 while preparing for potential commercial supply.

The global microspheres market is projected to grow from USD 4.36 billion in 2026 to USD 6.47 billion by 2031, at a CAGR of 8.23%, driven by stricter environmental and sustainability regulations. The solid microspheres segment is expected to grow faster than hollow microspheres due to their advantages in advanced manufacturing. The life science sector is forecast to be the second-fastest growing application, fueled by demand for precision diagnostics. Europe held the third-largest market share in 2025, with microspheres widely used in building materials to improve energy efficiency. Key players include 3M, Nouryon, and Thermo Fisher.

AustinPx has entered an agreement with Thermo Fisher Scientific's Patheon pharma services to install its KinetiSol Technology equipment at Thermo Fisher's oral solid drug manufacturing sites in Bend, Oregon, and Cincinnati, Ohio. The collaboration extends KinetiSol capabilities from development and scale-up through commercial manufacturing, with Thermo Fisher becoming the exclusive third-party CDMO provider offering the KinetiSol Formulator technology. KinetiSol is a solvent-free, fusion-based amorphous solid dispersion technology designed to enhance the bioavailability of poorly soluble drugs, and it has been used by more than 70 pharmaceutical and biotech companies since AustinPx launched in 2022. The agreement provides AustinPx's clients with a proven route to late-stage and commercial manufacturing and demonstrates the technology's commercial relevance for sponsors seeking a long-term amorphous solid dispersion strategy.

Thermo Fisher Scientific is expected to report fiscal second-quarter 2026 earnings per share of $5.71, up 6.5% from $5.36 a year ago. The company has beaten Wall Street estimates in each of the last four quarters. For the full year, analysts project EPS of $24.84, an 8.6% increase from fiscal 2025, with further growth to $27.18 expected in fiscal 2027. TMO stock has risen 24% over the past 52 weeks, outperforming the S&P 500 and the Health Care Select Sector SPDR ETF. Analysts rate the stock a Strong Buy with an average price target of $593.24, implying 17.1% upside.

Bernstein resumed coverage of Thermo Fisher Scientific with a Market Perform rating and a $520 price target, noting improvements in the life science tools and diagnostics sector. The firm highlighted that new drug approvals, clinical trial starts, and funding have all increased over the past 12 months, and it expects stronger funding to translate into higher customer spending. Bernstein also pointed to re-shoring efforts and AI-driven demand for semiconductor-related tools as additional growth drivers. Earlier in June, Piper Sandler initiated coverage with a Neutral rating and a $510 price target, taking a cautious stance on the sector and recommending only Twist Bioscience due to its exposure to next-generation drug discovery.